Indivior Pharmaceuticals
INDV
76 hedge funds and large institutions have $1.04B invested in Indivior Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
0% more funds holding
Funds holding: 76 → 76 (0)
2.47% less ownership
Funds ownership: 49.41% → 46.94% (-2.5%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
46% less capital invested
Capital invested by funds: $1.91B → $1.04B (-$876M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$48.4M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$10.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.14M |
| 4 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$5.62M |
| 5 |
Citigroup
New York
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGIM
M&G Investment Management
London,
United Kingdom
|
-$71.7M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$60.5M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$27.8M |
| 4 |
Goldman Sachs
New York
|
-$21.7M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.3M |
INDV Hedge Fund Activity: Q4 2023 in Review
76 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2023, worth a combined $1.04B — down 46% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INDV positions and 6 closed out — a net gain of 1 holder — while 27 added to existing stakes and 26 trimmed.
The largest buyer was Barclays, adding an estimated $48.4M. The largest seller was M&G Investment Management, exiting entirely with an estimated $71.7M sold.
- 76 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.04B of Indivior Pharmaceuticals stock for Q4 2023, down 46% quarter-over-quarter.
- 7 funds opened new Indivior Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
- The largest Indivior Pharmaceuticals buyer in Q4 2023 was Barclays, an estimated $48.4M added.
- The largest Indivior Pharmaceuticals seller in Q4 2023 was M&G Investment Management, an estimated $71.7M sold.
Based on aggregated 13F filings for Q4 2023.